MedTrace Logo

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

NCT07454382 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-03-06

No results posted yet for this study

Summary

The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

Conditions

Interventions

BIOLOGICAL

Elranatamab-bcmm

Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody

DRUG

Cyclophosphamide

Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards

Sponsors & Collaborators

Principal Investigators

  • Alexander Lesokhin, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-27
Primary Completion
2029-08-27
Completion
2029-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07454382 on ClinicalTrials.gov